115 related articles for article (PubMed ID: 16148645)
1. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Pinthus JH; Sheffer Y; Nagler A; Fridman E; Mor Y; Genina O; Pines M
J Urol; 2005 Oct; 174(4 Pt 2):1527-31. PubMed ID: 16148645
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of prostate cancer xenografts by halofuginone.
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Abramovitch R; Dafni H; Neeman M; Nagler A; Pines M
Neoplasia; 1999 Oct; 1(4):321-9. PubMed ID: 10935487
[TBL] [Abstract][Full Text] [Related]
4. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
Sheffer Y; Leon O; Pinthus JH; Nagler A; Mor Y; Genin O; Iluz M; Kawada N; Yoshizato K; Pines M
Mol Cancer Ther; 2007 Feb; 6(2):570-7. PubMed ID: 17267660
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
7. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Nagler A; Genina O; Lavelin I; Ohana M; Pines M
Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.
Elkin M; Miao HQ; Nagler A; Aingorn E; Reich R; Hemo I; Dou HL; Pines M; Vlodavsky I
FASEB J; 2000 Dec; 14(15):2477-85. PubMed ID: 11099465
[TBL] [Abstract][Full Text] [Related]
9. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Pines M; Knopov V; Genina O; Lavelin I; Nagler A
J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model.
Abramson LP; Stellmach V; Doll JA; Cornwell M; Arensman RM; Crawford SE
J Pediatr Surg; 2003 Mar; 38(3):336-42; discussion 336-42. PubMed ID: 12632345
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
12. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.
Yee KO; Connolly CM; Pines M; Lawler J
Cancer Biol Ther; 2006 Feb; 5(2):218-24. PubMed ID: 16418571
[TBL] [Abstract][Full Text] [Related]
13. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.
Taras D; Blanc JF; Rullier A; Dugot-Senant N; Laurendeau I; Bièche I; Pines M; Rosenbaum J
Neoplasia; 2006 Apr; 8(4):312-8. PubMed ID: 16756723
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
[TBL] [Abstract][Full Text] [Related]
15. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA
Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935
[TBL] [Abstract][Full Text] [Related]
16. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Abu-Amara SN; Geiger B; Genina O; Monsonego-Ornan E; Pines M
J Hepatol; 2004 Feb; 40(2):269-77. PubMed ID: 14739098
[TBL] [Abstract][Full Text] [Related]
17. Halofuginone: an inhibitor of collagen type I synthesis.
Granot I; Halevy O; Hurwitz S; Pines M
Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor.
Pinthus JH; Fridman E; Dekel B; Goldberg I; Kaufman-Francis K; Eshhar Z; Harmelin A; Rechavi G; Mor O; Ramon J; Mor Y
J Urol; 2004 Oct; 172(4 Pt 2):1644-8. PubMed ID: 15371781
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
20. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y
Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
